Nautilus Unveils Tau Proteoforms Platform, Offering New Precision in Alzheimer’s Research

A new proteomics tool is enabling researchers to peer into the molecular chaos of Alzheimer’s disease, one protein variant at a time.

Nautilus Biotechnology has launched an Early Access Program for its single-molecule proteomics platform, starting with a tau proteoforms assay.

This technology tracks individual protein molecules and their variants (proteoforms), offering insights into tau’s role in neurodegenerative diseases like Alzheimer’s.

Sujal Patel, co-founder and CEO of Nautilus, said:

"Through years of validation, we’ve shown that our platform delivers reproducible, high-quality proteomic data with a level of resolution and scale that differentiates it from other approaches."

The Buck Institute for Research on Aging is using the platform to map hundreds of tau proteoforms across brain regions. Nautilus supports participants with data interpretation guidance to democratize access to advanced proteomics.

The technology could expand beyond tau to study proteins linked to Parkinson’s, ALS, and other age-related conditions.

A webinar on 14 January showcased the platform’s capabilities and collaboration with the Buck Institute.

The platform represents a methodological advancement over traditional protein analysis, enabling detailed study of proteoforms critical to understanding disease mechanisms.

⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.